NordicDx as
NordicDx AS is a Norwegian biotechnology company founded in 2020 that distributes the iaX universal reader for rapid diagnostic tests and provides ISO 17025/15189 accredited laboratory services across the Nordic region, serving consumers, healthcare providers, aquaculture operators, and industrial workplaces.
- Company typePrivate
- Founded2020
- HeadquartersStavanger, Norway
- Headcount1–10
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What NordicDx as does
NordicDx AS is a Norwegian biotechnology company founded in 2020 in Stavanger, Norway, that develops and distributes rapid diagnostic solutions across the Nordic region. The company sells CE-IVD approved rapid tests directly to consumers via its own e-commerce storefront (nordicdx.no) and provides accredited laboratory diagnostic services to healthcare institutions, aquaculture operators, and industrial workplaces. It serves nine diagnostic sectors spanning human health, aquaculture, food safety, water and environment, livestock, plant health, emergency medicine, public health preparedness, and veterinary practice under a One Health framework.
The company's core technology is the iaX platform, developed by technology partner Assaya and distributed by NordicDx in the Nordic region. iaX is positioned as the world's first universal reader for rapid diagnostic tests (Lateral Flow Assays): a portable, Class 1 IVD medical device (CE-marked under EU IVDR 2017/746) that converts qualitative rapid tests from multiple manufacturers (Abbott, BD, Roche, Abnova, Alltest, BTNX) into quantitative, cloud-connected digital results in 5–20 minutes. The platform is complemented by ISO 17025 and ISO 15189 accredited laboratory services using PCR, qPCR, and isothermal amplification, with a flexible accreditation scope for medical microbiology (M16, viral analyses from body fluids) approved in November 2025. NordicDx has expanded its product line with the LEIQA series (recyclable, low-environmental-impact quantitative assays) and is developing NDx-ListeriaControl, a rapid test for Listeria monocytogenes detection in seafood, in collaboration with Nofima, Cermaq, and Assaya.
NordicDx operates a hybrid go-to-market model. The B2C channel sells individual rapid tests at 70–180 NOK per unit, fulfilled from its Stavanger warehouse with 1–3 day delivery in Norway. The B2B channel uses direct enterprise sales to deliver bulk volumes, accredited laboratory analyses, mobile testing stations, and tailored diagnostic solutions to clinics, hospitals, oil and gas operators, and aquaculture producers. Revenue streams include one-time hardware and product sales (iaX reader and rapid test kits), professional services for accredited laboratory analyses, and multi-year B2B contracts. To date the company has been funded primarily through non-dilutive research grants, including a 7 million NOK grant from FHF (September 2025) and seed funding from HelseCampus Stavanger (February 2025), rather than disclosed equity rounds.
NordicDx as firmographics
Firmographics- Name
- NordicDx as
- Legal name
- NordicDx AS
- Website
- https://nordicdx.no
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- NordicDx AS is a Norwegian biotechnology company founded in 2020 that distributes the iaX universal reader for rapid diagnostic tests and provides ISO 17025/15189 accredited laboratory services across the Nordic region, serving consumers, healthcare providers, aquaculture operators, and industrial workplaces.
- Ownership category
- akta.pro rank
NordicDx as industry classification
Industry- Product category
- In-Vitro Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Laboratory & Point-of-Care Diagnostic Devices (Analyzers, Test Kits, Microscopy) (HLAMAFAI)
- akta.pro secondary industries
- Point-of-Care & In-Clinic Diagnostics (Rapid Tests, Benchtop Analyzers) (HLAMADAI), Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL), Home-Use & OTC Rapid Self-Tests (Consumer POCT kits) (HLAHAOAK)
Keywords
Where NordicDx as is headquartered
LocationHeadquarters
- HQ city
- Stavanger
- HQ country
- Norway
- HQ region
- Europe
Offices1 record
Markets served
NordicDx as business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
Revenue model
- Rapid Test Sales (B2C & B2B): NordicDx sells CE-IVD approved rapid tests directly to consumers and healthcare providers via its own e-commerce shop and to businesses/institutions in B2B volumes. Product range spans infection, allergy, hormone, gastrointestinal, vitamin, and substance tests. Orders fulfilled from Stavanger warehouse with 1-3 day delivery in Norway.
- Accredited Laboratory Services: ISO 17025 and ISO 15189 accredited diagnostic services including virus analysis from body fluids (M16), bespoke diagnostic method development, RT-PCR and qPCR analysis, and industry/workplace testing. Services are offered to healthcare institutions, research organizations, and industrial clients.
- iaX Hardware & Platform: Sale of the iaX universal rapid test reader — the core hardware platform. The iaX reader enables quantitative digital results from rapid tests, with secure cloud storage, API integration to clinical systems, and centralized dashboards for herd/health management.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Individual consumer rapid tests (single units) |
| Other | Multi-year contract | B2B / institutional volumes |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels4 records
NordicDx as product offering
Product offeringCore offering
NordicDx AS develops, manufactures, and distributes the iaX universal reader platform and CE-IVD-marked rapid diagnostic test kits for human, animal, and environmental health applications. The company also operates an ISO 17025/15189-accredited laboratory that provides fee-for-service diagnostic testing alongside its proprietary SAVD RT-PCR and LEIQA product lines.
Product overview
NordicDx AS offers a diagnostic platform centered on the iaX Reader, the world's first universal smart reader for rapid diagnostic tests (Class 1 IVD medical device). The platform converts traditional lateral flow assays from multiple manufacturers into quantitative, cloud-connected digital results. Complementary offerings include the NordicDx Express App and OpenBIO Web Portal for data management, plus ISO 17025/15189 accredited laboratory services covering PCR, qPCR, and isothermal amplification. The product portfolio includes over 7 CE-IVD rapid tests spanning infection (COVID/influenza/RSV multiplex, CRP, UTI, Borrelia, Legionella), gastrointestinal (H. pylori, Celiac, blood in stool), allergy (cat, house dust mite), hormone/fertility, vitamin/nutrition, and drug/substance categories. The LEIQA series provides next-generation low-environmental-impact quantitative assays for humans, animals and environmental testing.
Differentiator
Problem solved
Functional benefit
Brands
- iaX: The world's first universal reader for rapid diagnostic tests. A portable, Class 1 IVD approved device that delivers accurate, quantitative and connected results from many test manufacturers. Powered by mains or battery, with secure cloud storage.
- SAVD
- LEIQA
- NDx-ListeriaControl
Products and services
- iaX Universal Reader Platform Multi-format diagnostic reader instrument designed to run rapid immunoassays and molecular assays on a single platform, intended for clinical laboratories, veterinary practices, food and environmental testing organizations, and consumer users under the One Health positioning.
- SAVD RT-PCR RT-PCR molecular diagnostic product line offered by NordicDx as part of its CE-IVD diagnostic portfolio for human, animal, and environmental health applications.
- LEIQA Quality-control offering within the NordicDx diagnostic product portfolio, supporting validated diagnostic workflows alongside the iaX reader platform.
- CE-IVD Rapid Diagnostic Test Kits CE-IVD-marked rapid diagnostic test kits designed for human, animal, and environmental health screening, sold both to enterprise laboratory customers and directly to consumers via the company's online store.
- ISO 17025/15189 Accredited Laboratory Services Fee-for-service diagnostic testing delivered through NordicDx's ISO 17025 and ISO 15189 accredited laboratory, providing analytical testing services to clinical, veterinary, food, and environmental customers.
Quantifiable outcome
- 100% sensitivity demonstrated for iaX platform in serum samples (Journal of Virological Methods, SSI/University of Copenhagen study)
- +3 more outcomes
Companies that use NordicDx as
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles4 records
NordicDx as technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability4 records
Feature6 records
NordicDx as partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- Statens Serum Institut (SSI)coreDanish public health research institute that collaborated with NordicDx and the University of Copenhagen on a peer-reviewed study validating the iaX platform. The study, accepted for publication in the Journal of Virological Methods, demonstrated 100% sensitivity for the iaX platform using automated machine reading of lateral flow assays in serum samples.
- University of CopenhagencoreAcademic research partner alongside Statens Serum Institut in the study validating the iaX platform. The collaboration contributed to proof-of-concept publication in Journal of Virological Methods, validating laboratory-grade quality in a rapid-test format.
- NofimacoreAcademic research partner in the NDx-ListeriaControl FHF project (project 910119). Nofima is a Norwegian food research institute that prepared the knowledge summary on Listeria monocytogenes and upcoming EU regulatory changes. Collaborates with NordicDx to develop a rapid diagnostic system for Listeria monocytogenes detection in the seafood industry.
- Cermaq NorwaycoreIndustrial partner in the NDx-ListeriaControl FHF project. Cermaq is a salmon farming company providing industrial expertise and real-world production environment context for the development of the Listeria rapid diagnostic system.
- AssayacoreTechnology partner in the NDx-ListeriaControl FHF project and the iaX platform technology provider. Assaya developed the iaX reader (world's first universal reader for rapid diagnostic tests) and the assayaDX test platform. NordicDx is the Nordic region distributor for Assaya's iaX technology. Assaya also provides sustainable, affordable diagnostic tools without plastic in 100% recyclable materials.
- UroScanminorCollaboration partner in the BladderAI project, co-funded by the EU DESIRE initiative. The project successfully advanced early bladder cancer detection. Completed September 2024.
- Norway Health TechminorNordicDx is a member of Norway Health Tech, Norway's largest health ecosystem with over 350 partners. The cluster connects industry, research, and healthcare to industrialize solutions that strengthen patient care nationally and globally. Provides networking and collaboration opportunities within Norway's health technology sector.
- Stiim Aqua ClusterminorNordicDx is a member of Stiim Aqua Cluster, a technology-driven innovation network working for sustainable growth in the aquaculture industry. The membership provides a unique arena for technology transfer and collaboration, enabling NordicDx to bring its rapid-testing expertise and iaX platform directly into the seafood sector.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
NordicDx as competitors and assessment
Company assessmentBroad incumbents
- QuidelOrtho: QuidelOrtho markets the Sofia rapid diagnostic reader, one of the established LFA readers in the market. It is comparable as a POC LFA reader competitor with broader installed base and IVD menu than NordicDx's iaX, though Sofia is a proprietary rather than universal reader.
- IDEXX Laboratories: IDEXX is the global leader in companion animal diagnostics and serves veterinary practices with rapid in-clinic tests and reference lab services. It is comparable as a peer in the veterinary and One Health diagnostics segments that NordicDx addresses with its iaX platform.
- Roche Diagnostics: Roche is one of the LFA test manufacturers integrated with iaX and operates the cobas Liat POC molecular system. It is comparable as a global IVD incumbent across both rapid antigen and molecular POC diagnostics, with much broader scale and menu than NordicDx.
- BD (Becton Dickinson): BD manufactures LFA tests (including the BD Veritor system reader) that are compatible with the iaX platform. BD is a comparable broad IVD incumbent in rapid diagnostics with global distribution and a proprietary reader platform.
- Abbott Diagnostics: Abbott is one of the LFA test manufacturers explicitly supported by the iaX platform and is a global IVD incumbent with broad rapid test offerings (Binax, Panbio). It is comparable as both a potential partner (tests readable on iaX) and a competitor in POC diagnostics.
Emerging players
- Atomo Diagnostics: Atomo Diagnostics develops integrated POC rapid test devices (AtomoRapid) for infectious disease and consumer health. It is an emerging peer in the integrated POC rapid diagnostics category, with comparable platform-level ambition though smaller commercial scale than NordicDx.
Direct peers
- Mesa Labs: Mesa Labs provides lateral flow readers and rapid test quality-control solutions to IVD manufacturers and clinical labs. It is a direct peer in the LFA reader infrastructure category that NordicDx competes in via the iaX platform.
- Quansys Biosciences: Quansys Biosciences produces the Q-View multiplex LFA reader and quantitative assay kits for research and clinical use. It is a direct peer in the quantitative LFA reader category that NordicDx's iaX also targets.
- Detekt Biomedical: Detekt Biomedical is a European-based developer of POC diagnostic readers and lateral flow readers for clinical and field use. It is a direct peer in the universal LFA reader category where NordicDx's iaX competes.
- Assaya: Assaya developed the iaX universal reader technology and the assayaDX test platform, and NordicDx acts as Assaya's Nordic region distributor under a strategic technology partnership. Assaya is the closest direct peer because it owns the underlying platform technology NordicDx commercializes.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
NordicDx as social profiles
Digital presenceNordicDx as compliance and trust
Trust signalCompliance5 records
NordicDx as financial estimates
Financial estimateRevenue estimate
Valuation estimate
NordicDx as leadership team
Management profileNumber of profiles
Profiles1 record
NordicDx as funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NordicDx as M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NordicDx as
What does NordicDx as do?
NordicDx AS develops, manufactures, and distributes the iaX universal reader platform and CE-IVD-marked rapid diagnostic test kits for human, animal, and environmental health applications. The company also operates an ISO 17025/15189-accredited laboratory that provides fee-for-service diagnostic testing alongside its proprietary SAVD RT-PCR and LEIQA product lines.
Is NordicDx as a public or private company?
NordicDx as is a private company. It is classified as unknown and is currently operating.
When was NordicDx as founded?
NordicDx as was founded in 2020. It employs 1 to 10 people.
Where is NordicDx as based?
NordicDx as is headquartered in Stavanger, Norway, in the Europe region.
How does NordicDx as make money?
Three revenue lines are on record. Rapid Test Sales (B2C & B2B) is the primary driver. The others are accredited Laboratory Services and iaX Hardware & Platform.
Who are NordicDx as's main competitors?
Broad incumbents on record are QuidelOrtho, IDEXX Laboratories, Roche Diagnostics, BD (Becton Dickinson) and Abbott Diagnostics. Atomo Diagnostics is listed as an emerging player. Direct peers are Mesa Labs, Quansys Biosciences, Detekt Biomedical and Assaya.
Does NordicDx as have an API?
Yes. Open REST API that integrates with existing medical records and laboratory systems. Enables real-time data transmission, dashboards and alerts.
What industry is NordicDx as in?
NordicDx as's product category is In-Vitro Diagnostics. Its primary akta.pro industry code is HLAMAFAI, Laboratory & Point-of-Care Diagnostic Devices (Analyzers, Test Kits, Microscopy), with a secondary code of HLAMADAI, Point-of-Care & In-Clinic Diagnostics (Rapid Tests, Benchtop Analyzers). Its NAICS code is 325413 and its SIC code is 3826.